RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

GoInformatics, TeselaGen form strategic partnership to offer cutting-edge biodesign automation tools

GoInformatics, TeselaGen form strategic partnership to offer cutting-edge biodesign automation tools

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Cholesterol-lowering drugs could be alternative treatment for people who take statins

Cholesterol-lowering drugs could be alternative treatment for people who take statins

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam advances Tuschl II patent estate through the USPTO

Alnylam advances Tuschl II patent estate through the USPTO

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam third quarter 2012 revenues decrease to $16.8 million